What Georgia Patients Should Know About Ozempic and Gastroparesis

Latest update (2026-01)

FDA enforcement record (Ongoing): Presence of Particulate Matter: Hair was found in a prefilled syringe. [source]

From General Health Information to Targeted Risk Awareness

If you're experiencing persistent nausea, vomiting, or abdominal pain after taking Ozempic, you may be dealing with gastroparesis. The medical community has long studied how GLP-1 receptor agonists affect gastric emptying, and recent reports have raised new concerns. This page provides a clear timeline of events and regulatory context surrounding Ozempic and gastroparesis in Georgia.

Understanding the Link Between Ozempic and Gastroparesis

Ozempic, the brand name for semaglutide, is a glucagon-like peptide-1 receptor agonist (GLP-1 RA) approved for the management of type 2 diabetes and, more recently, for chronic weight management. While its efficacy in glycemic control and weight loss is well-documented, a growing body of evidence links its use to significant gastrointestinal adverse effects, including gastroparesis. Gastroparesis is a disorder characterized by delayed gastric emptying in the absence of mechanical obstruction, leading to symptoms such as nausea, vomiting, early satiety, and abdominal pain. This section examines the clinical presentation of gastroparesis, the pharmacological mechanisms by which Ozempic may trigger it, and the risk and settlement considerations for affected patients in Georgia. Clinical Presentation and Diagnosis of Gastroparesis Gastroparesis presents with a constellation of symptoms that can significantly impair quality of life. Common manifestations include chronic nausea, vomiting (often of undigested food), postprandial fullness, bloating, and upper abdominal discomfort. Diagnosis typically involves a history of these symptoms and objective evidence of delayed gastric emptying, often via gastric emptying scintigraphy. The condition can be idiopathic or secondary to diabetes, surgery, or medications. In the context of Ozempic use, the onset of gastroparesis may be insidious, with patients initially attributing symptoms to the drug's known gastrointestinal side effects. However, persistent or severe symptoms warrant further evaluation, as standard fasting protocols may not ensure gastric emptying in patients on GLP-1 RA therapy, particularly during medication up-titration or in those with coexisting gastrointestinal motility disorders (https://pubmed.ncbi.nlm.nih.gov/41573454/).

Pharmacological Evidence and Reported Adverse Effects

Ozempic (semaglutide) works by mimicking the action of the incretin hormone GLP-1, which stimulates insulin secretion, suppresses glucagon release, and slows gastric emptying. This latter effect is central to its therapeutic action but also underlies its gastrointestinal adverse effects. In placebo-controlled trials, gastrointestinal adverse reactions occurred more frequently among patients receiving Ozempic than placebo (placebo 15.3%, Ozempic 0.5 mg 32.7%, Ozempic 1 mg 36.4%). The majority of reports of nausea, vomiting, and/or diarrhea occurred during dose escalation. More patients receiving Ozempic 0.5 mg (3.1%) and Ozempic 1 mg (3.8%) discontinued treatment due to gastrointestinal adverse reactions than patients receiving placebo (0.4%). In the trial with Ozempic 1 mg and 2 mg, gastrointestinal adverse reactions occurred more frequently among patients receiving Ozempic 2 mg (34.0%) vs Ozempic 1 mg (30.8%) (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166). Additionally, less common gastrointestinal adverse reactions with a frequency of <5% included dyspepsia (1.9% placebo, 3.5% 0.5 mg, 2.7% 1 mg), eructation (0%, 2.7%, 1.1%), flatulence (0.8%, 0.4%, 1.5%), gastroesophageal reflux disease (0%, 1.9%, 1.5%), and gastritis (0.8%, 0.8%, 0.4%) (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166). These data indicate a dose-dependent increase in gastrointestinal adverse events, with higher doses associated with greater incidence.

Mechanistic Pathways Linking Ozempic to Gastroparesis

The primary mechanism by which Ozempic can induce gastroparesis is through its effect on gastric motility. GLP-1 RAs delay gastric emptying by inhibiting antral contractions and stimulating pyloric tone, a process mediated by vagal and enteric nervous system pathways. This pharmacological action, while beneficial for postprandial glucose control, can become pathological in susceptible individuals, leading to clinically significant gastroparesis. The case report of a patient who held semaglutide for 12 days, completed bowel preparation, and fasted from solids for 32 hours and clear liquids for 10 hours, yet still had a distended antrum containing fluid and particulate matter consistent with a full stomach, underscores the profound and prolonged effect of GLP-1 RAs on gastric emptying. Endoscopy confirmed substantial residual gastric contents exceeding 200 mL (https://pubmed.ncbi.nlm.nih.gov/41573454/). This suggests that standard preoperative fasting guidelines may be inadequate for patients on Ozempic, and that the drug's effect on gastric motility can persist well beyond its dosing interval.

Risk Anchors and Settlement Considerations for Georgia Patients

The adequacy of warnings regarding Ozempic and gastroparesis is a critical risk anchor. While the prescribing information for Ozempic lists gastrointestinal adverse reactions, including nausea, vomiting, diarrhea, dyspepsia, and gastroesophageal reflux disease, it does not explicitly mention gastroparesis as a potential adverse effect. The label notes that gastrointestinal adverse reactions occurred more frequently among patients receiving Ozempic than placebo and that the majority occurred during dose escalation (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166). However, the absence of a specific warning for gastroparesis may leave patients and healthcare providers unaware of the risk, particularly in cases where symptoms are severe or persistent. For patients in Georgia who have developed gastroparesis after using Ozempic, settlement-related considerations may include the strength of the causal link between the drug and the condition, the timing of symptom onset relative to drug initiation, and the adequacy of informed consent. The timeline between exposure and documented harm is crucial; in the case report, the patient had been on semaglutide therapy, and despite holding the drug for 12 days, gastric emptying remained impaired (https://pubmed.ncbi.nlm.nih.gov/41573454/). This suggests that harm can occur even after discontinuation, complicating the assessment of causation. For affected patients, settlement considerations may involve evaluating whether the manufacturer provided sufficient warnings about the risk of gastroparesis, whether the patient's symptoms were appropriately managed, and whether the drug's benefits outweighed the risks in their specific case. Given the dose-dependent nature of gastrointestinal adverse reactions, patients on higher doses (e.g., 2 mg) may be at greater risk. Legal claims may focus on failure to warn, design defect, or negligence. In Georgia, plaintiffs must demonstrate that the drug was defective and that the defect caused their injury. The evidence of delayed gastric emptying persisting after drug cessation (https://pubmed.ncbi.nlm.nih.gov/41573454/) may support claims of long-term harm. Additionally, the high rate of discontinuation due to gastrointestinal adverse reactions (3.1% for 0.5 mg and 3.8% for 1 mg) (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166) indicates that a significant subset of patients experience intolerable side effects, which may include gastroparesis.

Important Notice

This page is for educational and informational purposes only. It does not provide medical diagnosis, treatment, or legal advice. Consult licensed clinicians and qualified attorneys for case-specific decisions.

Frequently Asked Questions

What is gastroparesis and how is it linked to Ozempic?

Gastroparesis is a disorder characterized by delayed gastric emptying in the absence of mechanical obstruction, leading to symptoms such as nausea, vomiting, early satiety, and abdominal pain. Ozempic (semaglutide) can induce gastroparesis by slowing gastric emptying through its action as a GLP-1 receptor agonist. This effect can become pathological in susceptible individuals, causing clinically significant gastroparesis that may persist even after drug discontinuation (https://pubmed.ncbi.nlm.nih.gov/41573454/).

What are the settlement considerations for Ozempic-related gastroparesis in Georgia?

Settlement considerations include the strength of the causal link between Ozempic and gastroparesis, the timing of symptom onset relative to drug initiation, and the adequacy of warnings provided by the manufacturer. In Georgia, plaintiffs must prove that the drug was defective and caused their injury. Evidence of delayed gastric emptying persisting after drug cessation (https://pubmed.ncbi.nlm.nih.gov/41573454/) and the absence of a specific gastroparesis warning in the label (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166) may support legal claims.

What symptoms should prompt a medical evaluation for Ozempic users?

Persistent or severe gastrointestinal symptoms such as chronic nausea, vomiting of undigested food, postprandial fullness, bloating, and upper abdominal discomfort should prompt medical evaluation. These symptoms may indicate gastroparesis, especially if they occur during Ozempic use or persist after discontinuation. Standard fasting protocols may not ensure gastric emptying in patients on GLP-1 RA therapy (https://pubmed.ncbi.nlm.nih.gov/41573454/).

Does submitting information create an attorney-client relationship?

No. Submission requests an initial records screening only and does not create an attorney-client relationship.

Information Registry: individuals with documented Ozempic exposure and a confirmed Gastroparesis diagnosis may request an independent eligibility review. [Begin Assessment]

References

Request a Free Case Review

This page is for educational and informational purposes only and is not medical or legal advice. Consult a licensed professional for case-specific guidance.